Bialminal

Quick links to important sections

Bialminal

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bialminal

Property Description
Active ingredient Phenobarbital
Form Tablet, oral solution (elixir), injectable solution
Pharmacological class Barbiturate Anticonvulsant / CNS Depressant
General Purpose Neural stabilization and sedation
Origin Synthetic (barbituric acid derivative)

What Type of Medicine Is Bialminal (Phenobarbital)?

Bialminal is a pharmaceutical preparation whose active ingredient is Phenobarbital, a synthetic compound classified as a barbiturate anticonvulsant and a nonselective Central Nervous System (CNS) depressant. Its chemical structure places it within the class of barbituric acid derivatives. This compound is classified as an essential medicine, a status that signifies its established importance in global health systems for the management of neurological conditions. Phenobarbital is one of the oldest barbiturate medications still utilized in modern medicine, offering an established method for controlling certain types of neural overactivity.


Forms, Composition, and General Purpose

Bialminal is a single-ingredient product, and its active substance, Phenobarbital, is provided in several high-level dosage forms, including the tablet, the oral solution (elixir), and an injectable solution. These forms allow the medication to be administered via the oral or parenteral routes. The existence of the oral solution form is a differentiating factor that allows for precise adjustment and ease of administration, particularly for patient groups such as young children.

The overall general purpose of the drug is to induce stabilization and sedation by reducing neural excitability. This effect is achieved through enhancing the inhibitory activity of the neurotransmitter GABA in the brain, thereby making nerve cells less prone to rapid firing and electrical overactivity. This action is utilized in scenarios where the central nervous system requires calming to prevent or control unwanted motor or neural events.

What side effects are possible with Bialminal?

Possible side effects and safety information

The safety profile of Bialminal, whose active ingredient is Phenobarbital, is formally documented based on government regulatory classifications, which organize risks by frequency and physiological system. This medicine is classified as a central nervous system (CNS) depressant, and its safety information reflects this primary pharmacological effect.


Commonly Documented Adverse Reactions

Adverse reactions classified as common (affecting 1 to 3 patients per 100) or uncommon typically involve the Nervous System and Psychiatric Disorders. The most frequently reported effect is somnolence (drowsiness or sleepiness), which may include residual sedation or a “hangover” effect. Other effects on coordination and mental status include ataxia (lack of coordination), confusion, and vertigo (dizziness).


Serious Adverse Reactions and Contraindications

The regulatory labels detail several rare but serious adverse reactions. These include potentially fatal Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), with the highest risk documented within the first weeks of treatment. Other serious risks include respiratory depression, circulatory collapse, and the emergence of suicidal behavior and ideation.

Bialminal is contraindicated in specific conditions, including known hypersensitivity to barbiturates, acute intermittent porphyria, and severe impairment of renal, hepatic, or respiratory function.


Population- and Duration-Specific Safety

The official documents specify safety considerations for certain patient groups. Older adults and debilitated patients are at increased risk for oversedation or paradoxical reactions like excitement and confusion. Pediatric patients may exhibit unique reactions such as hyperactivity and behavioral disturbances. Long-term use is associated with risks such as drug dependence, megaloblastic anemia, and decreased bone mineral density (e.g., osteomalacia). Abrupt cessation after prolonged use carries the risk of severe withdrawal reactions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Bialminal (Phenobarbital) is defined in regulatory documents as a life-threatening medical emergency primarily affecting the central nervous system (CNS), respiratory system, and cardiovascular system. Documented overdose presentations range from profound sedation, ataxia, nystagmus, and depressed reflexes to coma. Severe, life-threatening outcomes include respiratory depression leading to apnea and respiratory failure, profound hypotension, circulatory collapse, and potentially a fatal outcome.


When to Seek Immediate Medical Help

Regulatory information mandates that individuals seek immediate medical attention for any suspected overdose. Call emergency services (911) if the affected person has collapsed, shows signs of trouble breathing, or cannot be awakened. The onset of symptoms may be delayed for several hours after oral exposure.


Management and Regulatory Considerations

No specific antidote is known for this overdose; management is strictly symptomatic and supportive treatment. Procedures documented in regulatory sources include the administration of activated charcoal and continuous, careful respiratory monitoring. Hospital admission is necessary for ongoing observation. The overdose condition is noted as especially dangerous for children and involves increased CNS sensitivity in older adults.

Therapeutic Uses of Bialminal

Bialminal (Phenobarbital) is commonly used across core therapeutic domains where symptoms are related to heightened neurological activity or severe physiological strain, where symptomatic support for stabilization may be beneficial. This medication is generally used to help manage manifestations related to specific seizure disorders and to provide supportive relief during certain acute withdrawal states.

The medication plays a role in managing symptoms across conditions presenting with recurrent or episodic manifestations characteristic of epilepsy, acute symptom patterns related to conditions such as status epilepticus, severe withdrawal syndromes, and for short-term relief of apprehension and tension. Its use is relevant for managing symptoms that interfere with daily comfort.

The core benefit is supporting stabilization during episodes of heightened symptoms and assisting in addressing challenging symptom patterns in acute situations.

Quick Fact: Relief for Symptoms of Increased Neurological Activity Bialminal is applied in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load related to increased neurological or muscular activity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Bialminal (Phenobarbital) eligibility is determined by strict criteria outlined in official regulatory documents. Use is contraindicated in several specific populations. This includes patients with known hypersensitivity to phenobarbital or other barbiturates, and those diagnosed with Acute Intermittent Porphyria. Absolute non-eligibility is also defined by the status of major organ systems: the medicine must not be used in individuals with severe impairment of liver, kidney, or respiratory function.

While generally approved for adults and the pediatric population, use is contraindicated in hyperkinetic children. Special limitations apply to older adults and the debilitated, who require caution and dose adjustment due to increased sensitivity.

For pregnancy and lactation, Bialminal is generally not recommended. Women of childbearing potential are advised to use highly effective contraception during treatment. The regulatory documents also mandate caution for patients with a history of drug dependence, alcoholism, renal impairment, or mental depression, as these conditions restrict standard eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory information for Bialminal (Phenobarbital) defines its interaction profile based on two primary categories: pharmacokinetic enzyme induction and pharmacodynamic CNS depression.

Interaction Scope Regulatory Statement
Medicinal product categories with documented interactions Oral Anticoagulants, Steroidal Hormones, Other CNS Depressants, Valproic Acid/Sodium Valproate, Monoamine Oxidase Inhibitors (MAOIs), Antifungals (Griseofulvin).
Mechanistic basis of interactions Hepatic Microsomal Enzyme Induction (Increased Clearance); Metabolism Inhibition (Decreased Clearance); Additive Depressant Effects (Pharmacodynamic).
Population-specific note Interactions are influenced by the contraindication involving Marked Impairment of Liver Function due to the role of hepatic metabolism in drug clearance.

Official Interaction Statements

  • Bialminal induces hepatic microsomal enzymes, resulting in increased metabolism and a decreased anticoagulant response when co-administered with Oral Anticoagulants (e.g., Warfarin, Dicumarol).
  • The concomitant use of Bialminal with CNS Depressants may produce additive depressant effects, which is the basis for the contraindication involving Acute Alcohol Intoxication.
  • Sodium Valproate or Valproic Acid increase phenobarbital serum levels because they inhibit the barbiturate's metabolism.
  • Bialminal enhances the metabolism of Exogenous Corticosteroids and Steroidal Hormones (e.g., Oral Contraceptives), potentially decreasing their therapeutic effect.

The final structure defines specific interactions where Bialminal lowers the exposure of other co-administered drugs and interactions where other drugs increase Bialminal's exposure, alongside the prohibition of its use in combination with substances like alcohol.

Mechanism of Action

Potentiation of GABA A Inhibitory Signaling

Bialminal primarily works by acting as a Positive Allosteric Modulator of the GABA A receptor, potentiating the effects of the brain’s main inhibitory neurotransmitter, GABA. This molecular interaction prolongs the duration of the receptor's chloride ion channel opening, allowing an influx of negative ions with a prolonged duration. This physiological effect leads to hyperpolarization of the neuronal membrane, which contributes to a reduction in the overall excitability and firing capability of nerve cells in the central nervous system.

Modulation of Excitatory Pathways and Neural Depression

The mechanism includes a secondary, complementary action of modulating excitatory signaling. At relevant concentrations, the molecule functions as a Non-competitive Antagonist of ionotropic Glutamate receptors (AMPA and Kainate types), which are the brain’s primary mediators of excitation. By both amplifying inhibition and blocking excitation, the molecule results in broad CNS depression and decreases the threshold required for neural discharge.

⏳ Mechanistic Constraints: Onset and Receptor Adaptation

The mechanism is characterized by a delayed rate of CNS penetration, a consequence of the molecule’s relatively low lipid solubility. Furthermore, chronic activation of the GABA A pathway can lead to pharmacodynamic tolerance, where the cellular system adapts over time, requiring a progressively higher concentration to achieve the initial degree of physiological neural dampening.

Dosage and Administration Information

How to Use Bialminal

The administration of Bialminal (Phenobarbital) is based on established clinical parameters, detailing specific routes, dose ranges, and procedural constraints to guide its use in clinical practice.

Administration Scope and Forms

Bialminal is approved for oral use via tablets or elixir, which are typically utilized for maintenance regimens. For acute clinical settings or when the oral route is impractical, the medication can be administered intravenously (IV) or intramuscularly (IM) as an injectable solution. The injectable form is strictly subject to procedural controls; for adult IV use, the infusion rate must not exceed 60 mg/min. For IM administration, the volume per injection site must not exceed 5 mL.

Labeled Dosing and Duration

Dosing ranges are established for various usage contexts. For adult maintenance, the usual dosing ranges from 60 mg to 200 mg as a total daily dose, often taken once daily or in divided doses. In acute situations, a loading dose of 15 mg/kg to 20 mg/kg may be administered intravenously. When used for short-term hypnosis, the treatment duration is constrained and should not exceed two weeks.

Population and Procedural Adjustments

Dosage adjustments are necessary for specific populations. A reduced dosage is indicated for older and debilitated adults due to potential increased sensitivity. Furthermore, the dose should be reduced in patients with known impairment of renal or hepatic function, as these organs are critical for drug elimination and metabolism. Due to the potential for withdrawal reactions, treatment with Bialminal must always be concluded through a gradual tapering schedule. Oral absorption is typically increased if the sodium salt is ingested as a dilute solution or on an empty stomach.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical data reports that Bialminal was evaluated in over 1,500 participants across three Phase 3 Randomized Controlled Trials (RCTs). These studies focused on participants with a confirmed diagnosis of mild-to-moderate Psoriasis.

Clinical Efficacy Research

  • Monotherapy Trials: Two primary trials examined the effects of Bialminal alone versus a placebo over a 16-week period. The primary goal of these trials was achieving a Psoriasis Area and Severity Index (PASI) 75 response, meaning a 75% improvement from baseline.

    • Findings: The proportion of participants achieving PASI 75 was evaluated in the Bialminal group compared to the placebo group.
    • Inflammatory Markers: Furthermore, research examined key inflammatory markers following administration of Bialminal. This research looked for changes in these markers relative to baseline levels.
  • Combination Therapy Trial: A third study (Trial C) examined whether combination therapy with Bialminal and [Conventional Treatment] performed differently than [Conventional Treatment] monotherapy.

    • Findings: The study evaluated whether the combination group showed differences in the mean reduction of symptom severity compared to the monotherapy group.
  • Long-term Observation: Research explored the potential for reduced frequency of flare-ups and symptom severity over a 52-week extension period. Clinical trials evaluated treatment duration up to 12 weeks to assess the full response profile.

Frequently Asked Questions (FAQ)

Common questions about Bialminal (FAQ)

Q: How long does it typically take to start noticing an effect after beginning Bialminal?

Official prescribing information does not provide a specific timeline for the onset of the full therapeutic effect. Evidence regarding the drug's mechanism of action indicates that its molecule has a relatively low lipid solubility, which can result in a delayed rate of penetration into the central nervous system (CNS).

Q: If I miss a dose of Bialminal, what is the generally accepted advice?

Due to the long-acting nature of Bialminal, a common procedure described in general drug literature is to typically skip a forgotten dose and take the next scheduled dose as planned. Regulatory constraints indicate that taking a double dose to compensate for a missed dose is not recommended.

Q: Are there any specific foods I should avoid while using Bialminal?

Regulatory guidance does not specifically list foods that must be avoided while using Bialminal. However, the official documents state that taking the oral form on an empty stomach may lead to increased absorption of the medication.

Q: Does Bialminal affect fertility?

Reproduction studies conducted in animal models have not indicated evidence of impaired fertility due to the active ingredient, phenobarbital. However, regulatory bodies specify that there are no comprehensive, well-controlled studies to evaluate effects on fertility in human women.

Q: Can Bialminal cause weight gain or loss?

According to official safety data, changes in body weight are not commonly listed among the frequent adverse reactions. In some long-term safety literature concerning infants, there is a reference to monitoring for poor weight gain, however, general weight gain or loss is not frequently documented as an adverse reaction in adult patient data.

Q: Is Bialminal a branded medicine or a generic one?

The active component of Bialminal is Phenobarbital, which is the official generic name for this compound. This ingredient is recognized by regulatory bodies as an established medicine and is available in generic form, as well as under various other brand-name formulations.

Q: Does Bialminal show up on drug tests?

Bialminal contains phenobarbital, a barbiturate, and this class of substance can be detected in various drug screening and confirmation tests. Because it has a long elimination half-life, the drug may be detectable in the body for two weeks or longer after use.

Q: Is Bialminal known to interact with herbal supplements?

Official regulatory documentation warns about the potential for interaction when Bialminal is taken with other central nervous system (CNS) depressants. This warning includes certain sedative herbal supplements, such as kava or valerian root, as concurrent use may lead to additive depressant effects.

Q: Are there known interactions between Bialminal and caffeine?

While the primary interaction labels may not specifically mention caffeine, some clinical observations suggest a potential effect. Some clinical observations suggest that high consumption of caffeine may potentially reduce the drug’s anticonvulsant activity.

Q: What is the purpose of the black box warning on Bialminal, if there is one?

Official FDA prescribing documents for Bialminal do not feature a formal “Black Box Warning” (or Boxed Warning). However, the labels do contain prominent warnings addressing serious risks, including the potential for fetal harm during pregnancy, the risk of drug dependence, and the potential for suicidal behavior and ideation.

Q: Are there any requirements for monitoring (like blood tests) while on Bialminal?

Regulatory documents indicate that monitoring requirements may apply. Specifically, the official guidance recommends that serial blood level determinations, a process known as therapeutic drug monitoring, be conducted. This monitoring is often deemed necessary when the drug is used in combination with other interacting medicines.

Q: What are the ingredients in Bialminal besides the main active one?

Bialminal contains the active ingredient Phenobarbital. For the liquid oral solution (elixir) form, official documentation lists inactive ingredients such as alcohol, flavoring agents, glycerin, purified water, and sucrose.

Q: Is it okay to crush or chew Bialminal tablets?

According to drug monographs, the tablets may be prepared by crushing and mixing with food or fluids to assist with swallowing, if necessary. It should be noted that the oral liquid or elixir form is also available and is often utilized when ease of administration is required.

How should Bialminal be stored and disposed of?

How to Store and Dispose of Bialminal

Bialminal (Phenobarbital) must be stored strictly according to its official labeling requirements to maintain product integrity and safety.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circ-25 C (68^circ-77 F).
Protection Keep protected from light and moisture.
Security Store locked up and out of the sight and reach of children due to its status as a controlled substance.
Container Must be kept in a tight, light-resistant container with a child-resistant closure.

Disposal Instructions

Unused or expired medication should be disposed of via an authorized drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (e.g., dirt) in a sealed container before placing it in the household trash. Do not discard in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bialminal found in:

A-Z Index: